The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cyclin dependent kinase 9 inhibition as a potential treatment for hepatocellular carcinoma.
 
Yu Yun Shao
No Relationships to Disclose
 
Hung-Wei Hsu
No Relationships to Disclose
 
Rita Robin Wo
No Relationships to Disclose
 
Han-Yu Wang
No Relationships to Disclose
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche/Genentech